Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Enhertu Hits Mark in 1st Line Breast Cancer with PIII Trial Win
Daiichi Sankyo and AstraZeneca said on April 21 that their antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) demonstrated superior efficacy over the current standard of care in the frontline treatment of HER2 positive metastatic breast cancer. Reporting the interim analysis results…
To read the full story
Related Article
- Enhertu Combo Snags EU Nod in 1st-Line HER2 Breast Cancer
September 2, 2026
- Enhertu Combo Scores China Nod in 1st-Line HER2 Breast Cancer
August 18, 2026
- Enhertu Combo Bags EU Panel Nod in 1st-Line HER2 Breast Cancer
July 28, 2026
- Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Enhertu Combo Filed for First-Line HER2 Breast Cancer in Japan
October 8, 2025
- Enhertu Combo Accepted for US Review in First-Line HER2 Breast Cancer
September 25, 2025
- Enhertu Combo Gets Breakthrough Tag for First-Line HER2 Breast Cancer
July 22, 2025
- Enhertu Entering New Phase of Growth with Early-Line Breast Cancer Data: CEO
June 4, 2025
- Enhertu Enters PIII for 1st Line HER2-Positive Breast Cancer
June 16, 2021
BUSINESS
- Lilly, Tanabe Signal Supply Restrictions over Suspected Mounjaro Misuse
November 9, 2026
- Celltrion to Lift Shipment Curbs on Japan’s 1st Actemra Biosimilar
November 9, 2026
- AstraZeneca Vows to Back Japanese Innovation with Global Potential
November 9, 2026
- Nippon Shinyaku Flags Possible IR Data Leak
November 9, 2026
- Espha Debuts NorLevo Generic in Japan
November 9, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…